Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Newly presented findings from the NEURO-TTRansform study identified thresholds for meaningful improvement in symptoms and disability, which were exceeded by eplontersen treatment.

Eplontersen Exceeds Established Thresholds for Symptom and Disability Improvement in ATTRv-PN

New findings confirm vutrisiran's long-term safety and efficacy in treating hereditary transthyretin amyloidosis, enhancing patient quality of life.

ATTRv-PN Treatment Vutrisiran Demonstrates Long-Term Efficacy in Open-Label HELIOS-A Extension

Videos

In this initial episode, experts Ari Green, MD, and Paul Tesar, PhD, break down the biological foundation and therapeutic importance of remyelination in multiple sclerosis.

Defining Remyelination in the Context of Multiple Sclerosis

Apnimed's AD109 shows promise in treating obstructive sleep apnea, achieving significant results in a landmark Phase 3 trial, paving the way for FDA approval.

Once-Daily Oral Pill for Obstructive Sleep Apnea Shows Promising Phase 3 Results, Paving Way for FDA Submission

AHN's neuro-oncology program aims to revolutionize brain and spine tumor care with innovative therapies, personalized treatment plans, and advanced research initiatives.

Rewiring Brain and Spine Tumor Care: AHN’s Coordinated, Personalized Approach   

, has been with the team since September 2022. Follow her on Twitter 

The assistant professor of neurology at Robert Wood Johnson Medical School discussed the mission of RCASIA, highlights from its annual retreat, and key takeaways from AAN 2025.

NeuroVoices: Brad Kamitaki, MD, on Aiming to Improve Dementia Care in Asian and Pacific American Communities

The executive vice president of research at the National MS Society talked about the significance of the Dystel Prize, honoring researchers in MS whose scientific work has led to meaningful diagnostic or therapeutic advancements. [WATCH TIME: 2 minutes]

Recognizing Scientific Excellence and Impact in Multiple Sclerosis Research: Bruce Bebo, PhD

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

PNS 2025

AAN 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

1rem

a headache neurologist and vice chair of BrainPac and the Headache & Facial Pain Section of AAN. It features articles on bringing lecanemab to neurology community clinics, a checklist for college age-people living with migraine, and a provider's cheat sheet to understanding sleep care; and a 

 examination of histone deacetylase inhibitors like givinostat in Duchenne muscular dystrophy.

Fall 2024

, the medical director of the MS Center at Holy Name Medical Center in Teaneck, New Jersey. It features articles on emerging MRI, OCT, CSF, and blood biomarkers for multiple sclerosis (MS); perspectives on self-managing MS via general consensus, insights from the MS-Selfie project, and a technology-based model; and a 

 examination of amifampridine in the treatment of Lambert-Eaton myasthenic syndrome and other neuromuscular junction disorders.

Summer 2024

Spring 2024

November 2023

October 2023

August 2023

June 2023

April 2023

February 2023

December 2022

November 2022

October 2022

August 2022

June 2022

April 2022

February 2022

December 2021

November 2021

October 2021

August 2021

June 2021

 Cure Connections special issue, "The Multiple Sclerosis Patient Journey," includes a review of key topics that impact patients with multiple sclerosis, including diagnosis, psychological implications, and treatments.  

The Multiple Sclerosis Patient Journey

April 2021

February 2021

This downloadable PDF provides you with insight and best practices from a collective of experts in the management of multiple sclerosis on the diagnosis and treatment of the disease, with a focus on the latest first-line therapies, balancing quality of life, managing fatigue, and the pipeline of future agents.